Novan — Investor Presentation (January 2023)
25 slides from Novan's investor presentation, Jan 6, 2023
Slide 1: Innovative Therapies for Skin Diseases
Innovative Therapies for Skin Diseases N A S D A Q : N O V N | n o v a n . c o m C O R P O R AT E P R E S E N TAT I O N / J A N UA R Y 2 0 2 3 Exhibit 99.2
Slide 2: Forward-Looking Statements
NOVAN.COM FORWARD-LOOKING STATEMENTS 2 This presentation contains forward-looking statements including, but not limited to, statements related to the timing of potential FDA approval of the Company’s new drug application (NDA) for berdazimer gel, 10.3% (SB206) for molluscum contagiosum, pricing and
Slide 3: Building a premier medical dermatology company
Building a premier medical dermatology company focused on developing and commercializing innovative therapeutic products for skin diseases
Slide 4: Investment Highlights
NOVAN.COM INVESTMENT HIGHLIGHTS 4 Anticipating FDA approval in first quarter 2024 (following a typical 12-month review) Potential to be the first FDA-approved prescription product for molluscum Commercial infrastructure ready to launch berdazimer gel, 10.3%, if approved U.S. market potential of ~6 m
Slide 5: Berdazimer Gel, 10.3% (SB206)
NOVAN.COM BERDAZIMER GEL, 10.3% (SB206) 51. 2023 Berdazimer gel 10.3% New Drug Application Novan. 2023. 2. Browning JC, Enloe C, Cartwright M, et al. JAMA Dermatol. 2022;158(8):871-878. 3.Cartwright M, Enloe C, Stripling S, Maeda-Chubachi T. J Drugs Dermatol. 2022;21(10):1104-1110. NOTES: B-SIMPLE4
Slide 6: Market Primed for a Topical Self-Administered Therapy
NOVAN.COM Market Primed for a Topical Self-Administered Therapy 6 Significant impact on quality-of-life for patients and caregivers1 Current therapies are cumbersome and potentially painful in-office procedures2 Caregivers and physicians are aligned in desire for effective prescription treatment1 Mo
Slide 7: Highly Contagious Skin Infection
NOVAN.COM HIGHLY CONTAGIOUS SKIN INFECTION Molluscum is caused by the molluscipoxvirus, a double-stranded DNA virus 1. Prevalence in the US of 5.1% to 11.5% in children aged 0-16 years. (Fam Pract. 2014 Apr;31(2):130-6). 2. Molluscum Contagiosum - Epidemiology Forecast – 2028. Seven Major Markets (U
Slide 8: Molluscum Impacts Daily Lives
NOVAN.COM MOLLUSCUM IMPACTS DAILY LIVES 8Source: Syneos Health, Digital ethnography research, July – September 2022 (n=13) Molluscum can create changes in how children see themselves, making them more nervous, cautious, or negatively conscious of their body Molluscum can limit children’s social deve
Slide 9: Market Research Indicates Current Lack of Treatment
NOVAN.COM MARKET RESEARCH INDICATES CURRENT “LACK OF” TREATMENT We Believe Lack of At-Home Therapeutic Option Results in Many Undiagnosed Cases1 9 Select HCPs Treatment Regimens PEDIATRICIAN 0.8% 8% 91% Referrer Treater Wait & See % Peds % ALL MC Patients 67% 4% <1% DERMATOLOGIST 0.2% 65% 35% Referr
Slide 10: Current Treatments Can Be Painful or Ineffective
NOVAN.COM CURRENT TREATMENTS CAN BE PAINFUL OR INEFFECTIVE Over 70% of Molluscum Patients go Untreated1,2 1. Syneos Health market research sponsored by Novan, Inc. 2. Basdag H, Rainer BM, Cohen BA. Molluscum contagiosum: to treat or not to treat? Experience with 170 children in an outpatient clinic
Slide 11: The Need for New Treatment Options
NOVAN.COM THE NEED FOR NEW TREATMENT OPTIONS High Demand from HCPs for Novel Treatment Solution 11Source: Syneos Health HCP Survey Results, August 2022. Q5. How would you rate the level of need for new drug therapy options for molluscum, on a scale of 1-7, where 1=no/minimal need and 7=very high nee
Slide 12: Willing to Prescribe Berdazimer Gel, 10.3%
NOVAN.COM WILLING TO PRESCRIBE BERDAZIMER GEL, 10.3% 1. Source: Syneos Health HCP Survey Results, August 2022. Q6. Assume Berdazimer 10.3% Gel is approved by the FDA for molluscum. How would you rate your willingness to prescribe Berdazimer 10.3% Gel for molluscum on a scale of 1-7 (1=very low/unwil
Slide 13: Payer, Pricing and Reimbursement
NOVAN.COM PAYER, PRICING AND REIMBURSEMENT1 , 2 1. Source: Syneos Health, Active Payer Primary Research, August 2022 (n=6) 2. Final pricing decisions may be made by Novan after due consideration of commercial, clinical, and legal factors. Syneos Health Consulting’s information, provided here, repres
Slide 14: Planning for Commercial Success
NOVAN.COM PLANNING FOR COMMERCIAL SUCCESS 14 Anticipating FDA Approval in Q1 2024 (following a typical 12-month review) Building awareness and excitement among dermatologist and pediatricians Educating on molluscum treatment vs. commonly used “watch and wait” Delivering best possible managed care co
Slide 15: Commercial Product Portfolio
NOVAN.COM Commercial Product Portfolio 15
Slide 16: Commercial Capabilities
NOVAN.COM COMMERCIAL CAPABILITIES 16 Established Presence Across the Dermatology Community ✓ Supply Chain And Market Access Well established dermatology specialty pharmacy network Comprehensive market access (payor strategy, patient assistance copay program) Established supply chain with 3rd party c
Slide 17: Delivered Year-Over-Year Growth Across Promoted Products
NOVAN.COM DELIVERED YEAR-OVER-YEAR GROWTH ACROSS PROMOTED PRODUCTS1 1. Source: IQVIA’s SMART Database – U.S. Edition 2. Commercial launch in the United States in Q3 2021 17 Q3 2022 TRx’s 37,900 10,085 12,417 Q3 YTD 2022 TRx’s 115,873 31,059 29,880 2021 TRx’s 117,436 10,033 25,213 YTD Q3’21 vs. Q3 22
Slide 18: Rhofade
NOVAN.COM 1: IQVIA National Prescription Audit, Moving Annual Total November 2022; 2: ”Understanding Rosacea.” Rosacea.org, accessed 10 Jan. 2022, https://www.rosacea.org/patients/materials/understanding-rosacea/what-is-rosacea; 3: Del Rosso JQ. Advances in understanding and managing rosacea: part 1
Slide 19: Wynzora Cream
NOVAN.COM 1. Wynzora® Cream [package insert]. MC2 Therapeutics; 2020; 2. Præstegaard M, Vestbjerg B, Selmer J, Holm-Larsen T. Phase 3 trial demonstrates superior patient treatment convenience of MC2-01 calcipotriene plus betamethasone dipropionate cream compared to current topical suspension. J of S
Slide 20: Minolira
NOVAN.COM 1: Indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older; 2: Minolira PI; 3: Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E et al. The burden of skin diseases: 2004 a joint project of the Amer
Slide 21: Corporate Overview
NOVAN.COM Corporate Overview 21
Slide 22: Proven Team with Expertise Across Drug Development and Commercialization
NOVAN.COM PROVEN TEAM WITH EXPERTISE ACROSS DRUG DEVELOPMENT AND COMMERCIALIZATION 22 Paula Brown Stafford, MPH President, Chief Executive Officer and Chairman Tomoko Maeda-Chubachi, MD, Ph.D., MBA Chief Medical Officer Carri Geer, Ph.D. SVP, Chief Technology Officer Brian M. Johnson, MBA Chief Comm
Slide 23: Financial Snapshot
NOVAN.COM FINANCIAL SNAPSHOT 23 1. With the December 2022 activity noted, the Company believes that its existing cash and cash equivalents, plus expected receipts associated with product sales from its commercial product portfolio, will provide it with adequate liquidity to fund its planned operatin
Slide 24: Focus Going Forward
NOVAN.COM 24 FOCUS GOING FORWARD Building a premier medical dermatology company focused on developing and commercializing innovative therapeutic products for skin diseases Driving towards potential approval of berdazimer gel, 10.3% (SB206) for treatment of molluscum in Q1 2024 Aligning commercial in
Slide 25: Thank You!
Innovative Therapies for Skin Diseases N A S D A Q : N O V N | n o v a n . c o m Thank You!